Tryptamines have been a well-studied family of chemical within the research chemical industry for many years. From the early days of AMT and various other compounds, Tryptamines have given scientists an important glimpse into the serotonin subgroup of receptors and their broad pharmacodynamic profiles.
5-MeO-MiPT (AKA 5-methoxy-N-methyl-N-isopropyltryptamine or Moxy) is yet another one of these exciting Tryptamines, being first published in the 1980’s, 5-MeO-MiPT has not been studied in vivo and has no official licensing for this purpose. However, since its popularity began to increase there has been some anecdotal reports of its use written in popular research chemical forums. Much of the discussion has been centered towards its entactogen properties, however, 5-MeO-MiPT sold on this site are strictly for in vitro research chemical purposes only.
Studies into 5-MeO-MiPT exist, making research somewhat simpler in terms of hypotheses to postulate. The main focus of this compound has been within the serotonin receptor subgroup. Both 5HT1A and 5HT2A have been identified as receptors for which 5-MeO-MiPT has some affinity. The 5HT2A receptor has a partial agonist reaction with 5-MeO-MiPT binding to it with slightly less affinity than the 5HT1A receptor. Further affinity and efficacy has been discussed for the SERT (serotonin) NET (noradrenalin) and MAO pathways.